Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NYSE:HNGR NASDAQ:IMAC NASDAQ:SGRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$27.84-2.6%$30.77$24.10▼$62.53$2.68B0.33767,621 shs891,936 shsHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AIMACIMAC$0.06$0.05$0.75▼$1.65$1.59M-0.88708,132 shs2,832 shsSGRYSurgery Partners$21.28-3.1%$22.22$18.87▼$33.97$2.81B1.821.32 million shs3.10 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-2.62%-10.16%-5.43%-17.54%-47.59%HNGRHanger0.00%0.00%0.00%0.00%0.00%IMACIMAC0.00%0.00%-3.21%+65.29%-96.55%SGRYSurgery Partners-3.05%+0.09%-3.36%-7.80%-29.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.3086 of 5 stars3.40.00.03.72.12.50.0HNGRHangerN/AN/AN/AN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AN/AN/AN/ASGRYSurgery Partners2.7453 of 5 stars3.41.00.00.03.10.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.80Moderate Buy$69.50149.64% UpsideHNGRHanger 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/ASGRYSurgery Partners 2.70Moderate Buy$33.3356.64% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, IMAC, CRNX, and SGRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025SGRYSurgery PartnersBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.007/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$36.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.005/27/2025SGRYSurgery PartnersBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $24.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M2,506.40N/AN/A$14.29 per share1.95HNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57IMACIMAC$15.22M0.10N/AN/A$0.69 per share0.09SGRYSurgery Partners$3.11B0.88$1.82 per share11.72$25.15 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)HNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/ASGRYSurgery Partners-$168.10M-$1.53N/A26.27N/A-6.10%2.41%0.99%8/5/2025 (Estimated)Latest HNGR, IMAC, CRNX, and SGRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13N/AN/AN/A$0.52 millionN/A8/5/2025Q2 2025SGRYSurgery Partners$0.16N/AN/AN/A$816.96 millionN/A5/12/2025Q1 2025SGRYSurgery Partners$0.08$0.04-$0.04-$0.30$777.77 million$776.00 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHNGRHangerN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A22.5322.53HNGRHanger3.711.230.85IMACIMAC0.011.271.27SGRYSurgery Partners1.091.891.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%HNGRHanger79.17%IMACIMAC24.27%SGRYSurgery PartnersN/AInsider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals4.60%HNGRHanger4.36%IMACIMAC10.00%SGRYSurgery Partners2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableHNGRHanger5,20039.12 million37.42 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableSGRYSurgery Partners15,000128.16 million125.21 millionOptionableHNGR, IMAC, CRNX, and SGRY HeadlinesRecent News About These CompaniesAlpine Associates Management Inc. Takes $13.54 Million Position in Surgery Partners, Inc. (NASDAQ:SGRY)July 31 at 4:24 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Stake in Surgery Partners, Inc. (NASDAQ:SGRY)July 31 at 3:46 AM | marketbeat.comSurgery Partners (SGRY) to Release Earnings on TuesdayJuly 30 at 7:31 AM | marketbeat.comBayforest Capital Ltd Makes New $1.02 Million Investment in Surgery Partners, Inc. (NASDAQ:SGRY)July 30 at 3:53 AM | marketbeat.comSurgery Partners (NASDAQ:SGRY) Shares Up 4.9% - Here's What HappenedJuly 29, 2025 | marketbeat.comSurgery Partners (NASDAQ:SGRY) Coverage Initiated at Bank of AmericaJuly 29, 2025 | americanbankingnews.comSurgery Partners (SGRY) Stock Trades Up, Here Is WhyJuly 28, 2025 | msn.comSurgery Partners (NASDAQ:SGRY) Earns Buy Rating from Analysts at Bank of AmericaJuly 28, 2025 | marketbeat.comFinancial Review: Danaher (NYSE:DHR) vs. Surgery Partners (NASDAQ:SGRY)July 28, 2025 | americanbankingnews.comSurgery Partners, Inc. (NASDAQ:SGRY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 27, 2025 | marketbeat.comVictory Capital Management Inc. Sells 371,195 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)July 23, 2025 | marketbeat.comSegall Bryant & Hamill LLC Has $3.53 Million Stake in Surgery Partners, Inc. (NASDAQ:SGRY)July 19, 2025 | marketbeat.comSurgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call ...July 18, 2025 | gurufocus.comSurgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call ...July 18, 2025 | gurufocus.comSurgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call DetailsJuly 18, 2025 | globenewswire.com18,817 Shares in Surgery Partners, Inc. (NASDAQ:SGRY) Bought by Teacher Retirement System of TexasJuly 18, 2025 | marketbeat.comWhy Surgery Partners (SGRY) Stock Is Trading Up TodayJuly 16, 2025 | msn.comSurgery Partners, Inc. (SGRY): A Bull Case TheoryJuly 15, 2025 | msn.com1 Healthcare Stock to Keep an Eye On and 2 to Be Wary OfJuly 7, 2025 | finance.yahoo.comCIBRA Capital Ltd Makes New Investment in Surgery Partners, Inc. (NASDAQ:SGRY)July 2, 2025 | marketbeat.comSurgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHNGR, IMAC, CRNX, and SGRY Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$27.84 -0.75 (-2.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$27.82 -0.02 (-0.05%) As of 08/1/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Hanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.IMAC NASDAQ:IMAC$0.06 0.00 (0.00%) As of 07/31/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Surgery Partners NASDAQ:SGRY$21.28 -0.67 (-3.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.24 -0.05 (-0.21%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
